ELI LILLY AND COMPANY |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 164.1 BRL | 0.00% |
|
+4.73% | +75.65% |
| 12:37pm | What other health conditions are weight-loss drugs being tested for? | RE |
| 12:36pm | Jefferies Adjusts Price Target on Eli Lilly to $1,015 From $994 | MT |
| Sales 2024 * | 42.98B 234B 3,395B | Sales 2025 * | 52.62B 287B 4,156B | Capitalization | 796B 4,339B 62,854B |
|---|---|---|---|---|---|
| Net income 2024 * | 11.93B 65.05B 942B | Net income 2025 * | 16.55B 90.24B 1,307B | EV / Sales 2024 * | 18.9 x |
| Net Debt 2024 * | 18.06B 98.44B 1,426B | Net Debt 2025 * | 15B 81.76B 1,184B | EV / Sales 2025 * | 15.4 x |
| P/E ratio 2024 * |
66.1
x | P/E ratio 2025 * |
47.6
x | Employees | 43,000 |
| Yield 2024 * |
0.59% | Yield 2025 * |
0.68% | Free-Float | 99.8% |
More Fundamentals
* Assessed data
More news
Latest transcript on Eli Lilly and Company
More recommendations
More press releases
More news
| 1 week | +4.73% | ||
| Current month | +12.48% | ||
| 1 month | +17.80% | ||
| 3 months | +27.25% | ||
| 6 months | +78.05% | ||
| Current year | +75.65% |
1 week
158.26
167.16
1 month
135.70167.16
Current year
94.16167.16
1 year
69.46167.16
3 years
37.53167.16
5 years
13.56167.16
10 years
4.72167.16
| Managers | Title | Age | Since |
|---|---|---|---|
David Ricks
CEO | Chief Executive Officer | 56 | 31/12/95 |
Ruth Gimeno
PSD | President | - | - |
David Hyman
CTO | Chief Tech/Sci/R&D Officer | - | 15/10/23 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 63 | 24/01/21 | |
Ralph Alvarez
BRD | Director/Board Member | 68 | 31/03/09 |
Jon Fyrwald
BRD | Director/Board Member | 63 | 31/12/04 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 21/06/24 | 164.1 | 0.00% | 16,738 |
| 20/06/24 | 164.1 | -1.15% | 20,085 |
| 19/06/24 | 166 | +2.28% | 7,929 |
| 18/06/24 | 162.3 | +1.44% | 12,813 |
| 17/06/24 | 160 | +2.12% | 19,283 |
Delayed Quote Sao Paulo, June 21, 2024 at 09:05 pm
More quotes
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
Pharmaceuticals
Calendar
08/08/2024
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
883.9
USD
Average target price
856.2
USD
Spread / Average Target
-3.13%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +40.88% | 628B | |
| -5.10% | 358B | |
| +19.90% | 331B | |
| +9.95% | 301B | |
| +17.32% | 244B | |
| +3.80% | 228B | |
| +12.56% | 214B | |
| +6.99% | 165B | |
| -3.65% | 157B |
- Stock Market
- Equities
- LLY Stock
- LILY34 Stock
